Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration agreement with Google Cloud to revolutionize the biopharma medicine industry. By harnessing the powerful technologies of Google Cloud, including artificial intelligence (AI), Grifols aims to accelerate the development of new biopharma medicines.
The collaboration will involve the application of AI, particularly large language models, throughout the drug-development life cycle. This includes the identification of potential therapeutic candidates and the management of clinical trial programs, with the ultimate goal of significantly reducing the time required to bring new treatments to market.
Central to this collaboration will be the development of a new Grifols scientific information platform. This platform will leverage deep internal and external data sets owned by Grifols, allowing for rapid insights into diseases and pharmacology. By identifying disease-identifying biomarkers at an early stage, more effective treatments can be developed for patients. Additionally, this platform has the potential to uncover trends among specific patient groups, leading to more personalized medicine and improved health outcomes.
Grifols and Google Cloud will explore new applications and use cases for data and AI in the biopharma sector. They will also collaborate on sharing best practices in innovation, including the rapid testing and scaling of new technologies. By enhancing internal processes and fostering a culture of innovation, Grifols aims to boost team agility and productivity.
Albert Grifols Coma-Cros, Grifols Chief Scientific Innovation Officer, expressed his excitement about reinventing biopharma medicine with the help of Google Cloud’s advanced data technologies. He believes this collaboration will benefit patients and society by bringing more treatments to more people around the world.
Isaac Hernández, GM of Google Cloud Iberia, emphasized the potential of their data and generative AI capabilities to accelerate Grifols’ R&D efforts and improve patient care. By gaining new insights, discovering new drugs and therapies can be accelerated, and manufacturing processes can be made more efficient.
Grifols is a global healthcare company founded in Barcelona in 1909. It is committed to improving the health and well-being of people worldwide through the development, production, and provision of innovative healthcare services and solutions. With a presence in over 110 countries, Grifols focuses on treating a broad range of therapeutic areas, including immunology, hepatology, pulmonology, and neurology.
As a pioneer in the plasma industry, Grifols operates the world’s largest network of donation centers, spanning North America, Europe, Africa, the Middle East, and China. Additionally, the company offers a comprehensive portfolio of solutions in transfusion medicine, enhancing safety from donation to transfusion, and providing clinical diagnostic technologies.
With over 24,000 employees across more than 30 countries and regions, Grifols is committed to continuous innovation, quality, safety, and ethical leadership. In 2022, the company had an economic impact of EUR 9.6 billion in its core countries of operation and generated 193,000 jobs.
Grifols’ class A shares are listed on the Spanish Stock Exchange (MCE: GRF) as part of the Ibex-35. Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through American Depositary Receipts (NASDAQ: GRFS).
Please note that any future projections or assumptions in this article reflect the management team’s views at the time of writing and are subject to various factors that may impact actual results.
